Gulden Mesara was named senior vice president and chief communications and marketing officer.
Earlier this summer, NCI Director Ned Sharpless faced a big challenge: produce a video for kids with cancer at Camp Fantastic.
Budget increases in 2020 enabled NCI to boost funding for research project grants, pushing the payline up by two percentage points from last year's level.
FDA has accepted Karyopharm Therapeutics Inc.'s supplemental New Drug Application seeking approval for Xpovio—its first-in-class, oral selective inhibitor of nuclear export compound, as a new treatment for patients with multiple myeloma after at least one prior line of therapy.
NCI's Cancer Therapy Evaluation Program and Karyopharm Therapeutics Inc. have entered into a Cooperative Research and Development Agreement.
FDA has issued “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research, Draft Guidance for Industry,” which describes the FDA's current thinking on several topics relevant to clinical research related to the development of drugs containing cannabis or cannabis-derived compounds.
FDA has published the proposed new rule, Annual Summary Reporting Requirements under the Right to Try Act, that, when finalized, will implement a statutory requirement for sponsors and manufacturers to provide an annual summary to the FDA for any eligible investigational drug they provide to eligible patients under the Right to Try Act. jQuery(document).ready(function(){ jQuery('.people-thumb... […]
Researchers at the University of Arizona Health Sciences have developed a handheld device to bring skin cancer prevention and treatment options into more patient-care settings.
The American College of Surgeons Cancer Programs developed the Cancer Surgery Standards Program, a new program that aims to improve the quality of surgical care provided to cancer patients by implementing standards for cancer surgery and standardizing the way operative data are documented and communicated.
“It's the prices, stupid,” Uwe E. Reinhardt and authors famously wrote in their 2003 article describing the cause of high health care spending in the United States.1 Since then, multiple large analyses have confirmed that the prices of labor and goods, including pharmaceuticals and administrative costs, more so than differences in utilization, are the primary drivers of high health care spending.2,3
